<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984785</url>
  </required_header>
  <id_info>
    <org_study_id>unica</org_study_id>
    <nct_id>NCT04984785</nct_id>
  </id_info>
  <brief_title>Lipid Metabolism in Obese Subjects Undergoing Bariatric Surgery</brief_title>
  <official_title>Characterization of Physiological Mechanisms Involved in the Regulation of Eating Behavior for the Identification of Innovative Nutritional Strategies for Obese Patients Before and After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cagliari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Brotzu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cagliari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate modifications in the metabolism of polyunsaturated fatty&#xD;
      acids (PUFA) and biosynthesis of the lipid mediators N-acylethanolamines (NAE), both known to&#xD;
      induce and be induced by the nuclear peroxisome proliferator-activated receptor (PPAR)-α,&#xD;
      which may also explain the well-established improved lipid and energy metabolism after&#xD;
      bariatric surgery. The study is focused on understanding the weight loss mechanisms in order&#xD;
      to develop targeted dietary protocols.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study involves a careful preliminary medical history of the patients, with physical&#xD;
      examination, anthropometric parameters measurements and blood sampling for blood chemistry&#xD;
      routine and evaluation of any adverse events to assess suitability for the study. The evening&#xD;
      before bariatric surgery, one month and six months after bariatric surgery anthropometric&#xD;
      parameters measurements, blood sampling for blood chemistry routine, inflammatory and&#xD;
      lipid-metabolomic profile, and evaluation of any adverse events are performed. For the study&#xD;
      samples are stored identified by a code to be analyzed anonymously. Study interruption&#xD;
      criteria are: development of allergic reactions, ketonemia&gt; 1.5 mmol/L, acute gout&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">September 7, 2020</completion_date>
  <primary_completion_date type="Actual">November 4, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Modifications of Endocannabinoid and N-acylethanolamine plasma levels</measure>
    <time_frame>6 months</time_frame>
    <description>These lipid derivatives are involved in control of energy expenditure and lipid metabolism and are measured by LC MS/MS and expressed as nmol/ml plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight loss as kg, and fat mass reduction as total kg and percent of body mass</measure>
    <time_frame>6 months</time_frame>
    <description>Indicators of the success of the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in fatty acid plasma profile induced by bariatric surgery</measure>
    <time_frame>6 months</time_frame>
    <description>Fatty acid profile affect lipid derivatives. Fatty acid are measured by LC and GC and expressed as nmol/ml plasma</description>
  </primary_outcome>
  <enrollment type="Actual">68</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Lipid Metabolism Disorders</condition>
  <condition>Obesity</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for bariatric surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects with pathological obesity suitable for bariatric surgery&#xD;
&#xD;
          -  Body Mass Index (BMI) range 35-59&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  established diagnoses of a major disease (e.g., diabetes or kidney disease)&#xD;
&#xD;
          -  pregnancy or breastfeeding,&#xD;
&#xD;
          -  food allergies,&#xD;
&#xD;
          -  use of drugs that could affect lipid metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastiano Banni, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università di Cagliari</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro di Chirurgia Bariatrica dell'Azienda Ospedaliera G. Brotzu</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cagliari</investigator_affiliation>
    <investigator_full_name>Sebastiano Banni</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>Fatty Acids, Nonesterified</keyword>
  <keyword>Peroxisome Proliferator-Activated Receptors</keyword>
  <keyword>Endocannabinoids</keyword>
  <keyword>N-acylethanolamines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

